The University of Sao Paulo (Universidade de São Paulo, USP) is Brazil's most prestigious university and a leading research institution in Latin America. Founded in 1934, USP has grown to become one of the world's major research universities with approximately 120,000 students across multiple campuses[@uspneuroscience2024]. The university's neuroscience and neurodegeneration research programs have made significant contributions to understanding brain diseases in Latin American populations, with particular focus on the unique genetic, environmental, and clinical aspects of neurodegenerative diseases in Brazil.
The institution hosts the Brain Institute (Instituto do Cérebro - InC), established in 2017 as a major initiative to advance neuroscience research in Brazil[@inc2024]. USP's School of Medicine (Faculdade de Medicina da USP, FMUSP) houses one of the country's oldest and most productive neurology departments, with extensive clinical research programs in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[@fmusr2024].
The University of Sao Paulo (Universidade de São Paulo, USP) is Brazil's most prestigious university and a leading research institution in Latin America. Founded in 1934, USP has grown to become one of the world's major research universities with approximately 120,000 students across multiple campuses[@uspneuroscience2024]. The university's neuroscience and neurodegeneration research programs have made significant contributions to understanding brain diseases in Latin American populations, with particular focus on the unique genetic, environmental, and clinical aspects of neurodegenerative diseases in Brazil.
The institution hosts the Brain Institute (Instituto do Cérebro - InC), established in 2017 as a major initiative to advance neuroscience research in Brazil[@inc2024]. USP's School of Medicine (Faculdade de Medicina da USP, FMUSP) houses one of the country's oldest and most productive neurology departments, with extensive clinical research programs in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions[@fmusr2024].
| Attribute | Details |
|-----------|---------|
| Full Name | University of Sao Paulo (Universidade de São Paulo) |
| Portuguese Acronym | USP |
| Location | São Paulo, São Paulo, Brazil (main campus) |
| Campuses | São Paulo, Piracicaba, São Carlos, Ribeirao Preto, Bauru, Santos |
| Type | Public Research University |
| Founded | 1934 |
| Total Enrollment | ~120,000 students (undergraduate and graduate) |
| Faculty | ~6,000 professors |
| Website | [usp.br](https://www.usp.br) |
| Ranking | Top 100 globally (Times Higher Education, 2024) |
The University of Sao Paulo was founded in 1934 as part of a major modernization initiative in Brazilian higher education under the leadership of Governor Armando de Salles Oliveira. From its inception, USP was designed to be Brazil's premier research university, modeled on European and American research institutions. The university quickly established itself as the country's leading academic institution and has maintained that position for nearly a century[@brazilneuro2024].
The neuroscience programs at USP evolved gradually, beginning with the establishment of the Institute of Biosciences (Instituto de Biociências, IB) in the 1950s and the School of Medicine (Faculdade de Medicina da USP, FMUSP) which had already existed since 1912. The neurology department at FMUSP became a major center for neuroscience research in the latter half of the 20th century, focusing on clinical research in epilepsy, movement disorders, and cognitive disorders.
In 2017, USP established the Brain Institute (Instituto do Cérebro - InC) as a major initiative to accelerate neuroscience research in Brazil. The InC was designed as an interdisciplinary center bringing together researchers from biology, medicine, physics, engineering, and computer science to tackle fundamental questions in neuroscience and develop novel therapies for neurological disorders[@inc2024].
USP has developed comprehensive research programs in neurodegenerative diseases, with particular strengths in Alzheimer's disease, Parkinson's disease, and related conditions. The research is distributed across multiple institutes and departments, creating a collaborative environment for translational research from basic science to clinical application.
USP researchers have made significant contributions to understanding Alzheimer's disease in Latin American populations. The university participates in multi-center studies examining the prevalence, genetics, and clinical characteristics of Alzheimer's disease in Brazil[@brazilad2023].
Key research areas include:
Epidemiology and Prevalence Studies: USP researchers have conducted large-scale epidemiological studies establishing dementia prevalence rates in Brazilian populations. These studies have revealed important differences from North American and European cohorts, including earlier onset ages and higher prevalence of mixed pathology[@grinberg2008][@brucki2016]. The Brazilian Alzheimer's Disease Consortium, coordinated through USP, has established standardized protocols for dementia diagnosis across multiple centers in Brazil[@brazilad2023].
Biomarker Development: USP researchers are actively involved in developing and validating biomarkers for early Alzheimer's disease detection. Studies have examined cerebrospinal fluid biomarkers, including amyloid-beta, tau, and phospho-tau levels, in Brazilian patients. These studies have established reference values for Latin American populations and identified population-specific patterns[@chaves2023][@forlenza2015].
Genetics Research: Genetic studies at USP have examined APOE allele frequencies and their association with Alzheimer's disease in Brazilian populations. Research has identified unique genetic risk factors in Brazilian cohorts, including variants in genes related to lipid metabolism and inflammation[@nunes2020].
Clinical Trials: USP serves as a major clinical trial site for Alzheimer's disease therapeutics. The FMUSP Neurology Department participates in international multi-center trials for disease-modifying therapies, including monoclonal antibodies targeting amyloid-beta and tau[@fmusr2024].
The movement disorders program at USP is one of the most active in South America, with comprehensive research in Parkinson's disease, atypical parkinsonism, and other movement disorders.
Epidemiology: USP researchers have conducted systematic reviews and meta-analyses of Parkinson's disease prevalence in South American populations, establishing baseline rates and identifying potential environmental risk factors unique to the region[@martins2022].
Deep Brain Stimulation: USP neurosurgeons and neurologists have pioneered deep brain stimulation (DBS) procedures for Parkinson's disease in Brazil, developing protocols optimized for Brazilian patients and establishing long-term outcome registries.
Alpha-Synuclein Research: Basic science researchers at USP investigate alpha-synuclein aggregation mechanisms and their role in Parkinson's disease pathogenesis, with projects examining protein misfolding, propagation, and therapeutic targeting.
The neuroimaging program at USP has developed standardized protocols for MRI and PET imaging in neurodegenerative diseases. Research has focused on:
USP researchers are investigating stem cell-based therapies for neurodegenerative diseases through the Institute of Biomedical Sciences and the Stem Cell Laboratory. Current projects include:
USP hosts multiple research institutes and centers dedicated to neuroscience and neurodegeneration research:
The Institute of Biosciences conducts fundamental research in molecular neuroscience, cellular biology, and developmental neurobiology. Research groups study synaptic function, neuronal development, and the cellular mechanisms underlying neurodegeneration.
The FMUSP Neurology Department is the largest neurology department in Brazil, with over 100 faculty members conducting clinical and translational research. The department maintains active research programs in:
The Brain Institute (Instituto do Cérebro - InC) is USP's flagship neuroscience research center, featuring state-of-the-art facilities including:
The ICB conducts research in neuropharmacology, neurochemistry, and molecular neuroscience. Key areas include:
Researchers at the Institute of Psychology study cognitive neuroscience, neuropsychology, and rehabilitation. The center contributes to understanding cognitive decline and developing rehabilitation strategies for patients with neurodegenerative diseases.
The Butantan Institute, affiliated with USP, conducts biomedical research including studies on neurotoxins, drug development, and immunological approaches to neurological disease.
USP hosts numerous specialized laboratories conducting neurodegeneration research:
Laboratory of Neuroscience and Aging - Led by researchers at FMUSP, this laboratory focuses on biomarker studies, clinical characterization of cognitive decline, and longitudinal studies of aging in Brazilian populations.
Laboratory of Movement Disorders - This group studies Parkinson's disease and other movement disorders, with expertise in deep brain stimulation programming and clinical trials for new therapeutics.
Laboratory of Stem Cells and Regenerative Medicine - Researchers develop iPSC models of neurodegenerative diseases using cells from Brazilian patients, enabling studies of disease mechanisms and drug screening.
Laboratory of Neurogenetics - This laboratory conducts genetic screening in Brazilian families with neurodegenerative diseases, identifying novel mutations and characterizing known disease-causing variants in the local population.
Laboratory of Neuroimaging - Advanced neuroimaging research including MRI, PET, and emerging techniques for early diagnosis and disease monitoring.
Laboratory of Neuropharmacology - Studies drug mechanisms and develops novel therapeutic approaches for neurodegenerative diseases.
USP faculty have made significant contributions to neurodegeneration research:
USP provides comprehensive facilities for neurodegeneration research:
USP offers comprehensive training in neuroscience and neurodegeneration research:
USP maintains extensive international collaborations in neurodegeneration research:
| Disease | Research Intensity | Key Programs |
|---------|-------------------|--------------|
| Alzheimer's Disease | High | Biomarkers, genetics, clinical trials, neuroimaging |
| Parkinson's Disease | High | Movement disorders, DBS, alpha-synuclein biology |
| Vascular Dementia | Moderate-High | Stroke, vascular cognitive impairment |
| ALS | Moderate | Clinical trials, biomarkers |
| Frontotemporal Dementia | Moderate | Genetics, clinical characterization |
bertolucci2014, Guidelines for the diagnosis of dementia in Brazil (2014)
brazilad2023, Multi-center Alzheimer's disease research in Brazil: baseline characteristics (2023)
brazilneuro2024, State of neurodegeneration research in Brazil 2024 (2024)
brucki2016, Prevalence of dementia in Brazil: a systematic review (2016)
chaves2023, CSF biomarkers for Alzheimer's disease in Latin American populations (2023)
ferretti2010, Cognitive decline following brain trauma in Brazilian patients (2010)
fmusr2024, Clinical research in neurodegenerative diseases: 2023 annual review (2024)
forlenza2015, Translational research on biomarkers for Alzheimer's disease in Brazil (2015)
grinberg2008, Prevalence of Alzheimer's disease in Brazil: the Einstein/USP survey (2008)
inc2024, Brain Institute annual scientific report 2023 (2024)
jacobsen2019, Brazilian population studies on Alzheimer's disease: challenges and opportunities (2019)
lima2021, Neuroimaging findings in Brazilian Alzheimer's disease patients (2021)
martins2022, Parkinson's disease epidemiology in South America: a systematic review (2022)
nunes2020, Genetics of Alzheimer's disease in Brazilian cohorts: APOE and beyond (2020)
silva2024, Stem cell therapy for neurodegenerative diseases: Brazilian clinical trials (2024)
uspneuroscience2024, Annual report on neurodegeneration research 2023-2024 (2024)